Has Kishan Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,848 in general payments to Kishan Patel, MD across 20 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kishan Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kishan Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kishan Patel, MD

Retina Specialist · Dallas, TXNPI 1972957975

Payments from drug & device makers

$1,848in general payments, 2019–2025

Across 20 payments — averaging $92.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$887
Dutch Ophthalmic, USA$840
Biogen$66
Merck$31
Ocular Therapeutix, Inc.$24

What the payments were for

Travel & lodging$84045%
Food & beverage$1,00855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	16	$887
Dutch Ophthalmic, USA	1	$840
Biogen	1	$66
Merck	1	$31
Ocular Therapeutix, Inc.	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,848 in reported general payments places this provider in the 40th percentile of 108 retina specialist providers in Texas.

See all retina specialist providers in Texas →

Medicare billing

Part B allowed, 2024

$390,705

Medicare patients

436

Services billed

4,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
IlevroNepafenac	15	$8,107
Prednisolone Acetate	67	$3,278
Ketorolac Tromethamine	15	$619
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	25	$580
MoxifloxacinMoxifloxacin Hcl	13	$307
Latanoprost	26	$256
Ofloxacin	25	$239

Paid to pharmacies, not to this prescriber.

Other retina specialist in Dallas

Judy KimDallas$256K
Yu-Guang HeDallas$108K
Gregory KozielecDallas$4K
Noy AshkenazyDallas$3K
Brian BergerAustin$7.7M
Richard LaneSan Antonio$4.7M
Emmanuel ChangBellaire$3.7M
Jeremiah BrownSchertz$3M
Victor GonzalezMcAllen$2.1M
Courtney CrawfordBurleson$1.2M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →